{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:49:54Z","timestamp":1793332194845,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012443","name":"Maryland Stem Cell Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012443","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Spinal cord motor neurons (MNs) from human iPS cells (iPSCs) have wide applications in disease modeling and therapeutic development for amyotrophic lateral sclerosis (ALS) and other MN-associated neurodegenerative diseases. We need highly efficient MN differentiation strategies for generating iPSC-derived disease models that closely recapitulate the genetic and phenotypic complexity of ALS. An important application of these models is to understand molecular mechanisms of action of FDA-approved ALS drugs that only show modest clinical efficacy. Novel mechanistic insights will help us design optimal therapeutic strategies together with predictive biomarkers to achieve better efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We induce efficient MN differentiation from iPSCs in 4\u2009days using synthetic mRNAs coding two transcription factors (Ngn2 and Olig2) with phosphosite modification. These MNs after extensive characterization were applied in electrophysiological and neurotoxicity assays as well as transcriptomic analysis, to study the neuroprotective effect and molecular mechanisms of edaravone, an FDA-approved drug for ALS, for improving its clinical efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We generate highly pure and functional mRNA-induced MNs (miMNs) from control and ALS iPSCs, as well as embryonic stem cells. Edaravone alleviates H\n                      <jats:sub>2<\/jats:sub>\n                      O\n                      <jats:sub>2<\/jats:sub>\n                      -induced neurotoxicity and electrophysiological dysfunction in miMNs, demonstrating its neuroprotective effect that was also found in the glutamate-induced miMN neurotoxicity model. Guided by the transcriptomic analysis, we show a previously unrecognized effect of edaravone to induce the GDNF receptor RET and the GDNF\/RET neurotrophic signaling in vitro and in vivo, suggesting a clinically translatable strategy to activate this key neuroprotective signaling. Notably, edaravone can replace required neurotrophic factors (BDNF and GDNF) to support long-term miMN survival and maturation, further supporting the neurotrophic function of edaravone-activated signaling. Furthermore, we show that edaravone and GDNF combined treatment more effectively protects miMNs from H\n                      <jats:sub>2<\/jats:sub>\n                      O\n                      <jats:sub>2<\/jats:sub>\n                      -induced neurotoxicity than single treatment, suggesting a potential combination strategy for ALS treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides methodology to facilitate iPSC differentiation and disease modeling. Our discoveries will facilitate the development of optimal edaravone-based therapies for ALS and potentially other neurodegenerative diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-021-00510-y","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T08:03:58Z","timestamp":1641801838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Edaravone activates the GDNF\/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells"],"prefix":"10.1186","volume":"17","author":[{"given":"Qian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiping","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gege","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arens","family":"Taga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Maragakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6215-4959","authenticated-orcid":false,"given":"Mingyao","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"issue":"6","key":"510_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.neuron.2013.06.002","volume":"78","author":"LFR Qiang","year":"2013","unstructured":"Qiang LFR, Abeliovich A. Remodeling neurodegeneration: somatic cell reprogramming-based models of adult neurological disorders. Neuron. 2013;78(6):957\u201369. https:\/\/doi.org\/10.1016\/j.neuron.2013.06.002.","journal-title":"Neuron"},{"issue":"2","key":"510_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ana.23596","volume":"72","author":"DOH Ito","year":"2012","unstructured":"Ito DOH, Suzuki N. Accelerating progress in induced pluripotent stem cell research for neurological diseases. Ann Neurol. 2012;72(2):167\u201374. https:\/\/doi.org\/10.1002\/ana.23596.","journal-title":"Ann Neurol"},{"issue":"2","key":"510_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/WCO.0b013e3283518226","volume":"25","author":"YWHE Jung","year":"2012","unstructured":"Jung YWHE, Kim KY, et al. Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies. Curr Opin Neurol. 2012;25(2):125\u201330. https:\/\/doi.org\/10.1097\/WCO.0b013e3283518226.","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"510_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown","year":"2017","unstructured":"Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162\u201372. https:\/\/doi.org\/10.1056\/NEJMra1603471.","journal-title":"N Engl J Med"},{"key":"510_CR5","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fnins.2019.01310","volume":"13","author":"R Mejzini","year":"2019","unstructured":"Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310. https:\/\/doi.org\/10.3389\/fnins.2019.01310.","journal-title":"Front Neurosci"},{"key":"510_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/DNND.S135748","volume":"7","author":"M Hinchcliffe","year":"2017","unstructured":"Hinchcliffe M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis. 2017;7:61\u201370. https:\/\/doi.org\/10.2147\/DNND.S135748.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"9013","key":"510_CR7","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","volume":"347","author":"Amyotrophic Lateral Sclerosis\/Riluzole Study Group II ea","year":"1996","unstructured":"Amyotrophic Lateral Sclerosis\/Riluzole Study Group II ea. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347(9013):1425\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(96)91680-3.","journal-title":"Lancet"},{"key":"510_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD001447.pub3","volume":"3","author":"RGMJ Miller","year":"2012","unstructured":"Miller RGMJ, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS) motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3:1\u201334. https:\/\/doi.org\/10.1002\/14651858.CD001447.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"510_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","volume":"16","author":"K Abe","year":"2017","unstructured":"Abe K, Aoki M, et al. STe: safety and efcacy of edaravone in well defned patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505\u201312. https:\/\/doi.org\/10.1016\/S1474-4422(17)30115-1.","journal-title":"Lancet Neurol"},{"issue":"9","key":"510_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1474-4422(20)30265-9","volume":"19","author":"J Turnbull","year":"2020","unstructured":"Turnbull J. Reappraisal of an ALS trial: unaccounted procedural risk. Lancet Neurol. 2020;19(9):717\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(20)30265-9.","journal-title":"Lancet Neurol"},{"issue":"10","key":"510_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1474-4422(17)30289-2","volume":"16","author":"JS Mora","year":"2017","unstructured":"Mora JS. Edaravone for treatment of early-stage ALS. Lancet Neurol. 2017;16(10):772. https:\/\/doi.org\/10.1016\/S1474-4422(17)30289-2.","journal-title":"Lancet Neurol"},{"issue":"10","key":"510_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1474-4422(17)30290-9","volume":"16","author":"M Akimoto","year":"2017","unstructured":"Akimoto M, Nakamura K. Writing group on behalf of the Edaravone ALSSG: Edaravone for treatment of early-stage ALS - Authors' reply. Lancet Neurol. 2017;16(10):772. https:\/\/doi.org\/10.1016\/S1474-4422(17)30290-9.","journal-title":"Lancet Neurol"},{"issue":"sup1","key":"510_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/21678421.2017.1353101","volume":"18","author":"K Takei","year":"2017","unstructured":"Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):5\u201310. https:\/\/doi.org\/10.1080\/21678421.2017.1353101.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"4","key":"510_CR14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.cell.2017.10.011","volume":"171","author":"JD Rothstein","year":"2017","unstructured":"Rothstein JD. Edaravone: a new drug approved for ALS. Cell. 2017;171(4):742. https:\/\/doi.org\/10.1016\/j.cell.2017.10.011.","journal-title":"Cell"},{"issue":"1","key":"510_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nbt.3049","volume":"33","author":"Y Maury","year":"2015","unstructured":"Maury Y, Come J, Piskorowski RA, Salah-Mohellibi N, Chevaleyre V, Peschanski M, et al. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat Biotechnol. 2015;33(1):89\u201396. https:\/\/doi.org\/10.1038\/nbt.3049.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"510_CR16","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1038\/ncomms7626","volume":"6","author":"ZW Du","year":"2015","unstructured":"Du ZW, Chen H, Liu H, Lu J, Qian K, Huang CL, et al. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat Commun. 2015;6(1):6626. https:\/\/doi.org\/10.1038\/ncomms7626.","journal-title":"Nat Commun"},{"issue":"5","key":"510_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0896-6273(01)00413-5","volume":"31","author":"R Mizuguchi","year":"2001","unstructured":"Mizuguchi R, Sugimori M, Takebayashi H, Kosako H, Nagao M, Yoshida S, et al. Combinatorial roles of olig2 and neurogenin2 in the coordinated induction of pan-neuronal and subtype-specific properties of motoneurons. Neuron. 2001;31(5):757\u201371. https:\/\/doi.org\/10.1016\/S0896-6273(01)00413-5.","journal-title":"Neuron"},{"issue":"9","key":"510_CR18","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/nn.3467","volume":"16","author":"EO Mazzoni","year":"2013","unstructured":"Mazzoni EO, Mahony S, Closser M, Morrison CA, Nedelec S, Williams DJ, et al. Synergistic binding of transcription factors to cell-specific enhancers programs motor neuron identity. Nat Neurosci. 2013;16(9):1219\u201327. https:\/\/doi.org\/10.1038\/nn.3467.","journal-title":"Nat Neurosci"},{"issue":"2","key":"510_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/sctm.18-0036","volume":"8","author":"Y Xue","year":"2019","unstructured":"Xue Y, Zhan X, Sun S, Karuppagounder SS, Xia S, Dawson VL, et al. Synthetic mRNAs drive highly efficient iPS cell differentiation to dopaminergic neurons. Stem Cells Transl Med. 2019;8(2):112\u201323. https:\/\/doi.org\/10.1002\/sctm.18-0036.","journal-title":"Stem Cells Transl Med"},{"issue":"8","key":"510_CR20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.5966\/sctm.2013-0213","volume":"3","author":"J Sagal","year":"2014","unstructured":"Sagal J, Zhan X, Xu J, Tilghman J, Karuppagounder SS, Chen L, et al. Proneural transcription factor Atoh1 drives highly efficient differentiation of human pluripotent stem cells into dopaminergic neurons. Stem Cells Transl Med. 2014;3(8):888\u201398. https:\/\/doi.org\/10.5966\/sctm.2013-0213.","journal-title":"Stem Cells Transl Med"},{"issue":"9","key":"510_CR21","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1634\/stemcells.2007-0040","volume":"25","author":"L De Filippis","year":"2007","unstructured":"De Filippis L, Lamorte G, Snyder EY, Malgaroli A, Vescovi AL. A novel, immortal, and multipotent human neural stem cell line generating functional neurons and oligodendrocytes. Stem Cells. 2007;25(9):2312\u201321. https:\/\/doi.org\/10.1634\/stemcells.2007-0040.","journal-title":"Stem Cells"},{"issue":"8","key":"510_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37(8):907\u201315. https:\/\/doi.org\/10.1038\/s41587-019-0201-4.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"510_CR23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nbt.3122","volume":"33","author":"M Pertea","year":"2015","unstructured":"Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2015;33(3):290\u20135. https:\/\/doi.org\/10.1038\/nbt.3122.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"510_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139\u201340. https:\/\/doi.org\/10.1093\/bioinformatics\/btp616.","journal-title":"Bioinformatics"},{"issue":"3","key":"510_CR25","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","volume":"11","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 2010;11(3):R25. https:\/\/doi.org\/10.1186\/gb-2010-11-3-r25.","journal-title":"Genome Biol"},{"issue":"5","key":"510_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/jnr.24368","volume":"97","author":"Y Ohta","year":"2019","unstructured":"Ohta Y, Nomura E, Shang J, Feng T, Huang Y, Liu X, et al. Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis. J Neurosci Res. 2019;97(5):607\u201319. https:\/\/doi.org\/10.1002\/jnr.24368.","journal-title":"J Neurosci Res"},{"key":"510_CR27","doi-asserted-by":"publisher","unstructured":"Richner M, Jager SB, Siupka P, Vaegter CB. Hydraulic extrusion of the spinal cord and isolation of dorsal root ganglia in rodents. J Vis Exp. 2017. https:\/\/doi.org\/10.3791\/55226.","DOI":"10.3791\/55226"},{"issue":"6","key":"510_CR28","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0960-9822(95)00130-8","volume":"5","author":"YRH Tanabe","year":"1995","unstructured":"Tanabe YRH, Jessell TM. Induction of motor neurons by sonic hedgehog is independent of floor plate differentiation. Curr Biol. 1995;5(6):651\u20138. https:\/\/doi.org\/10.1016\/S0960-9822(95)00130-8.","journal-title":"Curr Biol"},{"issue":"3","key":"510_CR29","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/dvdy.21083","volume":"236","author":"TQCH Roelink","year":"2007","unstructured":"Roelink TQCH. The notch response inhibitor DAPT enhances neuronal differentiation in embryonic stem cell-derived embryoid bodies independently of sonic hedgehog signaling. Dev Dyn. 2007;236(3):886\u201392. https:\/\/doi.org\/10.1002\/dvdy.21083.","journal-title":"Dev Dyn"},{"issue":"5","key":"510_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuron.2013.05.029","volume":"78","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78(5):785\u201398. https:\/\/doi.org\/10.1016\/j.neuron.2013.05.029.","journal-title":"Neuron"},{"issue":"4","key":"510_CR31","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.stemcr.2017.08.019","volume":"9","author":"C Wang","year":"2017","unstructured":"Wang C, Ward ME, Chen R, Liu K, Tracy TE, Chen X, et al. Scalable production of iPSC-derived human neurons to identify tau-lowering compounds by high-content screening. Stem Cell Reports. 2017;9(4):1221\u201333. https:\/\/doi.org\/10.1016\/j.stemcr.2017.08.019.","journal-title":"Stem Cell Reports"},{"issue":"6562","key":"510_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/379257a0","volume":"379","author":"AN Akopian","year":"1996","unstructured":"Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature. 1996;379(6562):257\u201362. https:\/\/doi.org\/10.1038\/379257a0.","journal-title":"Nature"},{"issue":"24","key":"510_CR33","doi-asserted-by":"publisher","first-page":"13335","DOI":"10.1073\/pnas.94.24.13335","volume":"94","author":"K Khodakhah","year":"1997","unstructured":"Khodakhah K, Melishchuk A, Armstrong CM. Killing K channels with TEA+. Proc Natl Acad Sci U S A. 1997;94(24):13335\u20138. https:\/\/doi.org\/10.1073\/pnas.94.24.13335.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"510_CR34","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nn.4273","volume":"19","author":"S Sances","year":"2016","unstructured":"Sances S, Bruijn LI, Chandran S, Eggan K, Ho R, Klim JR, et al. Modeling ALS with motor neurons derived from human induced pluripotent stem cells. Nat Neurosci. 2016;19(4):542\u201353. https:\/\/doi.org\/10.1038\/nn.4273.","journal-title":"Nat Neurosci"},{"issue":"12","key":"510_CR35","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1523\/JNEUROSCI.4562-06.2007","volume":"27","author":"MA Johnson","year":"2007","unstructured":"Johnson MA, Weick JP, Pearce RA, Zhang SC. Functional neural development from human embryonic stem cells: accelerated synaptic activity via astrocyte coculture. J Neurosci. 2007;27(12):3069\u201377. https:\/\/doi.org\/10.1523\/JNEUROSCI.4562-06.2007.","journal-title":"J Neurosci"},{"issue":"7","key":"510_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040154","volume":"7","author":"T Takazawa","year":"2012","unstructured":"Takazawa T, Croft GF, Amoroso MW, Studer L, Wichterle H, Macdermott AB. Maturation of spinal motor neurons derived from human embryonic stem cells. PLoS One. 2012;7(7):e40154. https:\/\/doi.org\/10.1371\/journal.pone.0040154.","journal-title":"PLoS One"},{"issue":"1","key":"510_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2014.03.019","volume":"7","author":"BJ Wainger","year":"2014","unstructured":"Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Han SS, Sandoe J, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7(1):1\u201311. https:\/\/doi.org\/10.1016\/j.celrep.2014.03.019.","journal-title":"Cell Rep"},{"issue":"2","key":"510_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.bbagrm.2015.11.009","volume":"2015","author":"M Dell'Orco","year":"1859","unstructured":"Dell'Orco M, Milani P, Cereda C. Hydrogen peroxide-mediated induction of SOD1 gene transcription is independent from Nrf2 in a cellular model of neurodegeneration. Biochim Biophys Acta. 1859;2015(2):315\u201323. https:\/\/doi.org\/10.1016\/j.bbagrm.2015.11.009.","journal-title":"Biochim Biophys Acta"},{"key":"510_CR39","doi-asserted-by":"publisher","unstructured":"Rayon T, Stamataki D, Perez-Carrasco R, Garcia-Perez L, Barrington C, Melchionda M, et al. Species-specific pace of development is associated with differences in protein stability. Science. 2020;369(6510). https:\/\/doi.org\/10.1126\/science.aba7667.","DOI":"10.1126\/science.aba7667"},{"issue":"12","key":"510_CR40","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1369\/jhc.6A7008.2006","volume":"54","author":"PP Mammen","year":"2006","unstructured":"Mammen PP, Shelton JM, Ye Q, Kanatous SB, McGrath AJ, Richardson JA, et al. Cytoglobin is a stress-responsive hemoprotein expressed in the developing and adult brain. J Histochem Cytochem. 2006;54(12):1349\u201361. https:\/\/doi.org\/10.1369\/jhc.6A7008.2006.","journal-title":"J Histochem Cytochem"},{"issue":"6","key":"510_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020815","volume":"6","author":"J Zhu","year":"2011","unstructured":"Zhu J, Garcia-Barcelo MM, Tam PK, Lui VC. HOXB5 cooperates with NKX2-1 in the transcription of human RET. PLoS One. 2011;6(6):e20815. https:\/\/doi.org\/10.1371\/journal.pone.0020815.","journal-title":"PLoS One"},{"issue":"10","key":"510_CR42","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.jpedsurg.2008.11.055","volume":"44","author":"TY Leon","year":"2009","unstructured":"Leon TY, Ngan ES, Poon HC, So MT, Lui VC, Tam PK, et al. Transcriptional regulation of RET by Nkx2-1, Phox2b, Sox10, and Pax3. J Pediatr Surg. 2009;44(10):1904\u201312. https:\/\/doi.org\/10.1016\/j.jpedsurg.2008.11.055.","journal-title":"J Pediatr Surg"},{"issue":"5","key":"510_CR43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrn812","volume":"3","author":"MS Airaksinen","year":"2002","unstructured":"Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 2002;3(5):383\u201394. https:\/\/doi.org\/10.1038\/nrn812.","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"510_CR44","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.stem.2010.08.012","volume":"7","author":"L Warren","year":"2010","unstructured":"Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010;7(5):618\u201330. https:\/\/doi.org\/10.1016\/j.stem.2010.08.012.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"510_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nbt.3070","volume":"33","author":"TM Schlaeger","year":"2015","unstructured":"Schlaeger TM, Daheron L, Brickler TR, Entwisle S, Chan K, Cianci A, et al. A comparison of non-integrating reprogramming methods. Nat Biotechnol. 2015;33(1):58\u201363. https:\/\/doi.org\/10.1038\/nbt.3070.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"510_CR46","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1089\/hum.2015.045","volume":"26","author":"MA Poleganov","year":"2015","unstructured":"Poleganov MA, Eminli S, Beissert T, Herz S, Moon JI, Goldmann J, et al. Efficient reprogramming of human fibroblasts and blood-derived endothelial progenitor cells using nonmodified RNA for reprogramming and immune evasion. Hum Gene Ther. 2015;26(11):751\u201366. https:\/\/doi.org\/10.1089\/hum.2015.045.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"510_CR47","doi-asserted-by":"publisher","first-page":"42367","DOI":"10.1038\/srep42367","volume":"7","author":"SK Goparaju","year":"2017","unstructured":"Goparaju SK, Kohda K, Ibata K, Soma A, Nakatake Y, Akiyama T, et al. Rapid differentiation of human pluripotent stem cells into functional neurons by mRNAs encoding transcription factors. Sci Rep. 2017;7(1):42367. https:\/\/doi.org\/10.1038\/srep42367.","journal-title":"Sci Rep"},{"key":"510_CR48","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fneur.2018.00384","volume":"9","author":"S Stanga","year":"2018","unstructured":"Stanga S, Brambilla L, Kienlen-Campard P. A Role for GDNF and Soluble APP as Biomarkers of Amyotrophic Lateral Sclerosis Pathophysiology. Front Neurol. 2018;9:384.","journal-title":"Front Neurol"},{"issue":"16","key":"510_CR49","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1523\/JNEUROSCI.22-16-06920.2002","volume":"22","author":"LJ Wang","year":"2002","unstructured":"Wang LJ, Lu YY, Nakano I. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci. 2002;22(16):6920\u20138. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-16-06920.2002.","journal-title":"J Neurosci"},{"issue":"7","key":"510_CR50","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/stem.2825","volume":"36","author":"GM Thomsen","year":"2018","unstructured":"Thomsen GM, Avalos P, Ma AA, Alkaslasi M, Cho N, Wyss L, et al. Transplantation of neural progenitor cells expressing glial cell line-derived neurotrophic factor into the motor cortex as a strategy to treat amyotrophic lateral sclerosis. Stem Cells. 2018;36(7):1122\u201331. https:\/\/doi.org\/10.1002\/stem.2825.","journal-title":"Stem Cells"},{"key":"510_CR51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.7150\/ijms.5.92","volume":"5","author":"Z Zhao","year":"2008","unstructured":"Zhao Z, Lange DJ, Ho L, Bonini S, Shao B, Salton SR, et al. Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis. Int J Med Sci. 2008;5:92\u20139. https:\/\/doi.org\/10.7150\/ijms.5.92.","journal-title":"Int J Med Sci"},{"issue":"4","key":"510_CR52","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s11064-019-02725-4","volume":"44","author":"Y Noda","year":"2019","unstructured":"Noda Y, Motoyama S, Nakamura S, Shimazawa M, Hara H. Neuropeptide VGF-Derived Peptide LQEQ-19 has Neuroprotective Effects in an In Vitro Model of Amyotrophic Lateral Sclerosis. Neurochem Res. 2019;44(4):897\u2013904. https:\/\/doi.org\/10.1007\/s11064-019-02725-4.","journal-title":"Neurochem Res"},{"issue":"12","key":"510_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015307","volume":"5","author":"M Shimazawa","year":"2010","unstructured":"Shimazawa M, Tanaka H, Hara H, et al. An inducer of VGF protects cells against ER stress-induced cell death and prolongs survival in the mutant SOD1 animal models of familial ALS. PLoS One. 2010;5(12):e15307. https:\/\/doi.org\/10.1371\/journal.pone.0015307.","journal-title":"PLoS One"},{"issue":"1-2","key":"510_CR54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0014-5793(01)03227-6","volume":"510","author":"G Mandolesi","year":"2002","unstructured":"Mandolesi G, Gargano S, Pennuto M, Illi B, Molfetta R, Soucek L, et al. NGF-dependent and tissue-specific transcription of vgf is regulated by a CREB-p300 and bHLH factor interaction. FEBS Lett. 2002;510(1-2):50\u20136. https:\/\/doi.org\/10.1016\/S0014-5793(01)03227-6.","journal-title":"FEBS Lett"},{"issue":"34","key":"510_CR55","doi-asserted-by":"publisher","first-page":"10800","DOI":"10.1523\/JNEUROSCI.23-34-10800.2003","volume":"23","author":"J Alder","year":"2003","unstructured":"Alder J, Thakker-Varia S, Bangasser DA, Kuroiwa M, Plummer MR, Shors TJ, et al. Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J Neurosci. 2003;23(34):10800\u20138. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-34-10800.2003.","journal-title":"J Neurosci"},{"issue":"7","key":"510_CR56","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/1541-7786.MCR-06-0050","volume":"4","author":"L Cerchia","year":"2006","unstructured":"Cerchia L, D'Alessio A, Amabile G, Duconge F, Pestourie C, Tavitian B, et al. An autocrine loop involving ret and glial cell-derived neurotrophic factor mediates retinoic acid-induced neuroblastoma cell differentiation. Mol Cancer Res. 2006;4(7):481\u20138. https:\/\/doi.org\/10.1158\/1541-7786.MCR-06-0050.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"510_CR57","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00441-019-03128-1","volume":"379","author":"C Cocco","year":"2020","unstructured":"Cocco C, Corda G, Lisci C, Noli B, Carta M, Brancia C, et al. VGF peptides as novel biomarkers in Parkinson's disease. Cell Tissue Res. 2020;379(1):93\u2013107. https:\/\/doi.org\/10.1007\/s00441-019-03128-1.","journal-title":"Cell Tissue Res"},{"issue":"Issue 6, Supple","key":"510_CR58","doi-asserted-by":"publisher","first-page":"S221","DOI":"10.1212\/WNL.47.6_Suppl_4.221S","volume":"47","author":"PN Leigh","year":"1996","unstructured":"Leigh PN, Meldrum BS. Excitotoxicity in ALS. Neurology. 1996;47(Issue 6, Supplement 4):S221\u20137. https:\/\/doi.org\/10.1212\/WNL.47.6_Suppl_4.221S.","journal-title":"Neurology"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-021-00510-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-021-00510-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-021-00510-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T08:19:40Z","timestamp":1641802780000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-021-00510-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["510"],"URL":"https:\/\/doi.org\/10.1186\/s13024-021-00510-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.05.09.443325","asserted-by":"object"}]},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments involving human stem cells have been approved by the Johns Hopkins Medicine Institutional Review Board. The animal protocol was approved by the Johns Hopkins School of Medicine Animal Care and Use Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}